Prelude Therapeutics Receives FDA Clearance for Blood Cancer Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Should l Buy PRLD?
Source: seekingalpha
- FDA Trial Approval: Prelude Therapeutics has received FDA clearance to advance its blood cancer candidate PRT12396 into early-stage trials, marking a significant milestone in the company's efforts in hematologic oncology.
- Targeting Specific Cancer Types: PRT12396 is designed to treat a group of blood cancers known as myeloproliferative neoplasms, specifically targeting high-risk polycythemia vera and intermediate to high-risk myelofibrosis, with dosing expected to commence in Q2 2026.
- Multi-Center Study Design: The open-label, multi-center study aims to evaluate the safety and efficacy of PRT12396, with primary endpoints focusing on drug tolerability and effectiveness, laying the groundwork for future clinical applications.
- Gene-Targeted Therapy: PRT12396 is part of Prelude's JAK2V617F JH2 inhibitor program, targeting the key genetic mutation responsible for the progression of most myeloproliferative neoplasms, highlighting the company's strategic positioning in precision medicine.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRLD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRLD
About PRLD
Prelude Therapeutics Incorporated is a precision oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, it has developed a diverse pipeline consisting of multiple distinct programs, including kinases, targeted protein degraders, and degrader antibody conjugates. PRT12396 its lead, mutant-selective JAK2V617F inhibitor, is an open-label and multi-center study in patients with high-risk polycythemia vera and intermediate and high-risk myelofibrosis. JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms. The Company has discovered and is developing a series of selective and orally bioavailable KAT6A selective degraders. KAT6A is engaged in treating advanced breast cancer & other solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prelude Therapeutics Prices 18 Million Share Offering at $4.44 Each
- Offering Size: Prelude Therapeutics announced the pricing of 18,018,014 shares of common stock at $4.44 per share, with total gross proceeds expected to be approximately $90 million, which will significantly support the company's research and operational funding.
- Investor Participation: The offering was led by new investor RA Capital Management, with participation from Soleus Capital and other new and existing investors, indicating strong market confidence in the company's future prospects.
- Use of Proceeds: The company intends to utilize the net proceeds primarily for general corporate purposes, including funding research and clinical development of its product candidates and increasing working capital, thereby advancing its innovative drug pipeline.
- Compliance Statement: The registration statement for this offering was declared effective by the SEC on June 10, 2024, ensuring the legality and compliance of the issuance, which further enhances investor trust.
See More
Prelude Therapeutics Prices $90 Million Offering for Oncology Development
- Offering Size: Prelude Therapeutics priced its offering at $4.44 per share for 18.02 million shares, along with pre-funded warrants for 2.25 million shares, aiming for total gross proceeds of approximately $90 million to support general corporate purposes and R&D expenditures.
- R&D Progress: The offering is expected to close on April 21, 2026, with proceeds primarily allocated to advancing clinical and preclinical development of its oncology product candidates, particularly PRT12396 for polycythemia vera and myelofibrosis.
- Clinical Trial Plans: PRT12396 received IND clearance from the FDA in February 2026, with the first patient dosing anticipated in Q2 2026, marking a significant milestone in the company's oncology treatment efforts.
- Financial Position: As of December 31, 2025, Prelude reported $106 million in cash and equivalents, providing a cash runway into Q2 2027, indicating strong financial management and operational sustainability.
See More
Prelude Therapeutics Prices Public Offering at $4.44 per Share
- Offering Size: Prelude Therapeutics has priced a public offering of over 18 million shares of its voting common stock at $4.44 each, along with pre-funded warrants for up to 2.25 million additional shares at $4.4399 each, with gross proceeds estimated at approximately $90 million, indicating strong market support for its financing needs.
- Use of Proceeds: The company intends to utilize the net proceeds primarily for general corporate purposes, which may include funding research, preclinical and clinical development of its product candidates, increasing working capital, and capital expenditures, thereby laying a foundation for future product development.
- Investor Participation: The offering is led by new investor RA Capital Management, with participation from Soleus Capital and other new and existing healthcare-focused investors, demonstrating market confidence in Prelude and recognition of its potential growth prospects.
- Market Reaction: Following the announcement of the offering, Prelude Therapeutics shares rose 10.36% in premarket trading, reflecting investor optimism regarding the company's future developments and positive reception of its financing plans.
See More
Prelude Therapeutics Appoints New Chief Medical Officer
- Executive Appointment: Prelude Therapeutics announced that Charles Morris will join as Chief Medical Officer effective April 20, a move aimed at strengthening the company's clinical development capabilities to advance precision oncology.
- Extensive Experience: Prior to joining Prelude, Morris served as Chief Medical Officer at Lava Therapeutics and has held similar roles at Celyad Oncology and Radius Health, which is expected to bring valuable industry insights and leadership to the company.
- Strategic Implications: By bringing in an executive with a robust background, Prelude aims to enhance its market position in the competitive precision medicine sector and accelerate the progress of its clinical trials.
- Future Outlook: The appointment of the new Chief Medical Officer is seen as a significant step for Prelude Therapeutics' future development, potentially bringing new strategic directions and innovative thinking to the company.
See More
Prelude Therapeutics Appoints New Chief Medical Officer
- Executive Appointment: Prelude Therapeutics announced that Dr. Charles Morris will join as Chief Medical Officer on April 20, 2026, bringing over 30 years of oncology drug development experience, which is expected to provide strategic guidance for the company's clinical development of its two lead programs.
- Clinical Development Outlook: Dr. Morris's appointment comes at a pivotal time as the company anticipates its two leading programs targeting myeloproliferative neoplasms and ER+ breast cancer to enter clinical development in 2026, highlighting the company's strong growth potential in precision oncology.
- Extensive Industry Experience: Prior to joining Prelude, Dr. Morris served as Chief Medical Officer at Lava Therapeutics and contributed to multiple drug approvals at Celyad Oncology and Radius Health, indicating his deep expertise in oncology drug development.
- Innovative Drug Pipeline: Prelude Therapeutics focuses on developing innovative medicines with transformative potential, and Dr. Morris's leadership is expected to further advance the company's drug development efforts in areas of high unmet need, supporting its mission to extend precision medicine to every cancer patient in need.
See More
Prelude Therapeutics Reports 2025 Results and Pipeline Update
- Improved Financial Performance: Prelude Therapeutics reported a net loss of $99.5 million for 2025, translating to a loss of $1.29 per share, which is an improvement from the $127.2 million loss and $1.68 per share in 2024, primarily driven by reduced research and development expenses, indicating effective cost management.
- Strong Cash Position: The company ended 2025 with $106.4 million in cash, cash equivalents, restricted cash, and marketable securities, which is expected to fund operations into the second quarter of 2027, thereby enhancing financial stability for clinical development.
- Clinical Development Progress: Prelude plans to initiate a Phase 1 trial for PRT12396 in 2026, targeting high-risk polycythemia vera and intermediate-to-high-risk myelofibrosis patients, following FDA clearance of its IND application in the first quarter of 2026, marking a significant advancement in precision oncology.
- New Drug Development Outlook: PRT13722, a highly selective KAT6A degrader for ER-positive breast cancer, is expected to file its IND in mid-2026 with a Phase 1 study commencing in the second half of 2026, showcasing the company's ongoing commitment to innovative drug development.
See More
Prelude Therapeutics Prices 18 Million Share Offering at $4.44 Each
- Offering Size: Prelude Therapeutics announced the pricing of 18,018,014 shares of common stock at $4.44 per share, with total gross proceeds expected to be approximately $90 million, which will significantly support the company's research and operational funding.
- Investor Participation: The offering was led by new investor RA Capital Management, with participation from Soleus Capital and other new and existing investors, indicating strong market confidence in the company's future prospects.
- Use of Proceeds: The company intends to utilize the net proceeds primarily for general corporate purposes, including funding research and clinical development of its product candidates and increasing working capital, thereby advancing its innovative drug pipeline.
- Compliance Statement: The registration statement for this offering was declared effective by the SEC on June 10, 2024, ensuring the legality and compliance of the issuance, which further enhances investor trust.
See More
Prelude Therapeutics Prices $90 Million Offering for Oncology Development
- Offering Size: Prelude Therapeutics priced its offering at $4.44 per share for 18.02 million shares, along with pre-funded warrants for 2.25 million shares, aiming for total gross proceeds of approximately $90 million to support general corporate purposes and R&D expenditures.
- R&D Progress: The offering is expected to close on April 21, 2026, with proceeds primarily allocated to advancing clinical and preclinical development of its oncology product candidates, particularly PRT12396 for polycythemia vera and myelofibrosis.
- Clinical Trial Plans: PRT12396 received IND clearance from the FDA in February 2026, with the first patient dosing anticipated in Q2 2026, marking a significant milestone in the company's oncology treatment efforts.
- Financial Position: As of December 31, 2025, Prelude reported $106 million in cash and equivalents, providing a cash runway into Q2 2027, indicating strong financial management and operational sustainability.
See More
Prelude Therapeutics Prices Public Offering at $4.44 per Share
- Offering Size: Prelude Therapeutics has priced a public offering of over 18 million shares of its voting common stock at $4.44 each, along with pre-funded warrants for up to 2.25 million additional shares at $4.4399 each, with gross proceeds estimated at approximately $90 million, indicating strong market support for its financing needs.
- Use of Proceeds: The company intends to utilize the net proceeds primarily for general corporate purposes, which may include funding research, preclinical and clinical development of its product candidates, increasing working capital, and capital expenditures, thereby laying a foundation for future product development.
- Investor Participation: The offering is led by new investor RA Capital Management, with participation from Soleus Capital and other new and existing healthcare-focused investors, demonstrating market confidence in Prelude and recognition of its potential growth prospects.
- Market Reaction: Following the announcement of the offering, Prelude Therapeutics shares rose 10.36% in premarket trading, reflecting investor optimism regarding the company's future developments and positive reception of its financing plans.
See More
Prelude Therapeutics Appoints New Chief Medical Officer
- Executive Appointment: Prelude Therapeutics announced that Charles Morris will join as Chief Medical Officer effective April 20, a move aimed at strengthening the company's clinical development capabilities to advance precision oncology.
- Extensive Experience: Prior to joining Prelude, Morris served as Chief Medical Officer at Lava Therapeutics and has held similar roles at Celyad Oncology and Radius Health, which is expected to bring valuable industry insights and leadership to the company.
- Strategic Implications: By bringing in an executive with a robust background, Prelude aims to enhance its market position in the competitive precision medicine sector and accelerate the progress of its clinical trials.
- Future Outlook: The appointment of the new Chief Medical Officer is seen as a significant step for Prelude Therapeutics' future development, potentially bringing new strategic directions and innovative thinking to the company.
See More
Prelude Therapeutics Appoints New Chief Medical Officer
- Executive Appointment: Prelude Therapeutics announced that Dr. Charles Morris will join as Chief Medical Officer on April 20, 2026, bringing over 30 years of oncology drug development experience, which is expected to provide strategic guidance for the company's clinical development of its two lead programs.
- Clinical Development Outlook: Dr. Morris's appointment comes at a pivotal time as the company anticipates its two leading programs targeting myeloproliferative neoplasms and ER+ breast cancer to enter clinical development in 2026, highlighting the company's strong growth potential in precision oncology.
- Extensive Industry Experience: Prior to joining Prelude, Dr. Morris served as Chief Medical Officer at Lava Therapeutics and contributed to multiple drug approvals at Celyad Oncology and Radius Health, indicating his deep expertise in oncology drug development.
- Innovative Drug Pipeline: Prelude Therapeutics focuses on developing innovative medicines with transformative potential, and Dr. Morris's leadership is expected to further advance the company's drug development efforts in areas of high unmet need, supporting its mission to extend precision medicine to every cancer patient in need.
See More
Prelude Therapeutics Reports 2025 Results and Pipeline Update
- Improved Financial Performance: Prelude Therapeutics reported a net loss of $99.5 million for 2025, translating to a loss of $1.29 per share, which is an improvement from the $127.2 million loss and $1.68 per share in 2024, primarily driven by reduced research and development expenses, indicating effective cost management.
- Strong Cash Position: The company ended 2025 with $106.4 million in cash, cash equivalents, restricted cash, and marketable securities, which is expected to fund operations into the second quarter of 2027, thereby enhancing financial stability for clinical development.
- Clinical Development Progress: Prelude plans to initiate a Phase 1 trial for PRT12396 in 2026, targeting high-risk polycythemia vera and intermediate-to-high-risk myelofibrosis patients, following FDA clearance of its IND application in the first quarter of 2026, marking a significant advancement in precision oncology.
- New Drug Development Outlook: PRT13722, a highly selective KAT6A degrader for ER-positive breast cancer, is expected to file its IND in mid-2026 with a Phase 1 study commencing in the second half of 2026, showcasing the company's ongoing commitment to innovative drug development.
See More
